TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
WALTHAM, Mass., April 26, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
